Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
For more than 50 years, there has been considerable interest—and ongoing debate—as to the potential clinical benefits of interventions targeted to more intensively control elevated blood glucose levels in patients with acute myocardial infarction (MI) and, more recently, in those with acute coronary syndrome (ACS). In 1962, Sodi-Pallares et al introduced the glucose-insulin-potassium infusion (GIK) for treatment of acute MI.1,2 In 1972, Maroko and coworkers demonstrated a reduction in infarct size in dogs with experimental MI that were given an infusion of GIK.3 However, the use of GIK treatment for acute MI was largely abandoned over the ensuing years because of doubts and conflicting data about its efficacy, only to see interest return to this treatment when Diaz et al,4 on behalf of the Estudios Cardiológicos Latinoamérica (ECLA) Collaborative Group, showed a dramatic reduction in mortality after an acute MI from 11.5% in the control group to 6.7% in patients treated with GIK.
Dandona P, Boden WE. Intensive Glucose Control in Hyperglycemic Patients With Acute Coronary SyndromesStill Smoke, but No Fire…. JAMA Intern Med. 2013;173(20):1905–1906. doi:10.1001/jamainternmed.2013.8095
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: